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The activation and regulation of target genes by the tumour-suppressor p53 dictates the fate of a cell, with cell cycle arrest or
apoptosis being two distinct outcomes. PERP (p53 apoptosis effector related to PMP-22), a p53 transcriptional target, is induced
speciﬁcally during apoptosis but not cell cycle arrest. Downregulation of PERP is associated with the aggressive, monosomy
3-type of uveal melanoma (UM), the most common primary intraocular tumour in adults, and increased PERP expression has a
pro-apoptotic effect in UM cells. Here, we identify a novel effect of PERP expression, as elevated PERP protein positively
inﬂuences active levels of its own transcriptional regulator, p53. Using ﬂuorescent fusion proteins of PERP, p53 and MDM2, we
demonstrate in single living UM cells that PERP expression signiﬁcantly enhances p53 activity and its nuclear localization,
increases p53-dependent transcription (including that of MDM2) while allowing oscillatory nucleo-cytoplasmic shuttling of p53/
MDM2 complexes. Phosphorylation of p53 serine residues that interfere with the interaction between p53 and its negative
regulator MDM2 and enhance pro-apoptotic gene transcription also occurs subsequent to PERP expression. These results
implicate a role for PERP in amplifying functional p53 levels that promote p53-dependent apoptosis, and reveal a potential target
for exploitation in enhancing p53 activity.
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The regulation of p53 and of its impressive array of interacting
and target genes holds a central place among the molecular
mechanism(s)inﬂuencingthechoicebetweencellcyclearrest
and apoptosis.
1 The ability to engage in apoptosis is critical to
the tumour-suppressor role of p53 that is strongly supported
by the presence of p53 mutations in over half of human
cancers
2,3 and the compromised p53 activity by other
mechanisms in the majority of other cancers.
3 The latter
scenario points towards the deregulation of downstream p53
targets as a mechanism employed by tumour cells to evade
apoptosis. PERP (p53 apoptosis effector related to PMP-22)
was identiﬁed as a p53 transcriptional target that is distinc-
tively induced during apoptosis, and not cell cycle arrest,
4 and
consequently emerged as a prime candidate effector in the
p53-dependent apoptotic pathway. Subsequent studies con-
ﬁrmedthe pro-apoptoticrole forPERPin avariety ofcell types
and tissues,
5–8 with reported engagement of caspase-
dependent pathways.
5,8 However, the precise function of
PERP – a tetraspan protein primarily localized at the plasma
membrane – in eliciting an apoptotic response remains
unknown.
Cellular p53 levels are principally determined by the rate of
degradation – mostly but not entirely linked to the E3 ligase
activity of MDM2 – rather than synthesis.
3,9 Increased p53
stability in response to stress is achieved primarily through
decreased MDM2 protein levels and reduced p53-MDM2
interaction, while the ensuing elevated levels of transcription-
ally active p53 result in increased MDM2 transcription.
10,11
This p53-MDM2 regulatory feedback loop is essential in
maintaining tight regulation of p53 levels both in unstressed
and stressed cells, with additional control through post-
translational modiﬁcations, most notably phosphorylation of
key p53 serine (Ser) residues,
12 some of which inﬂuence the
p53-MDM2 interaction
13 and the nature of p53-target genes
transcribed.
14 (Co)localization and nuclear-cytoplasmic
shuttling of p53 and MDM2 also contribute to regulation of
p53 activity.
15,16
We have shown that PERP is an important molecular
determinant of apoptosis in primary uveal melanoma (UM)
tumours that is signiﬁcantly downregulated in the aggressive
monosomy-3 type, compared with less aggressive disomy-3
type of UM.
5,17 Downregulation of PERP (THW
18) was also
reported in tumours of the ovary, uterus and breast, and in
cutaneous melanoma, pancreas and mammary carcinoma
cell lines, compared with the respective normal tissues and
non-metastasizing cell lines.
18
The aim of this study was to investigate the effect of
increased PERP expression on its own upstream transcrip-
tional regulator, p53. For this purpose, we used the UM cell
line MEL202
19 that provides a biological background of low
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downstream of PERP.
5 Our results show that PERP
expression causes nuclear localization of p53 and increases
the level of transcriptionally active p53 protein, which also
presents posttranslational modiﬁcations known to inﬂuence
the p53–MDM2 interaction and to enhance the pro-apoptotic
gene transcription. Together, these results propose a novel
role for PERP in enhancing functional p53 levels and reveal a
potential new target forexploitation in the development of new
therapeutic agents aimed at increasing the endogenous p53
protein pool in neoplastic cells.
Results
PERP expression augments p53 protein level. To
investigate the effect of increased levels of PERP protein
on its transcriptional regulator p53, lysates of MEL202 cells
expressing green ﬂuorescent protein (GFP)–PERP were
analyzed by western blotting alongside lysates from control
non-transfected (NT) and GFP-only-transfected cells.
Signiﬁcantly increased levels of p53 protein were observed
in MEL202 cells expressing GFP–PERP compared with
control cells, in which p53 was barely detectable (Figure 1a).
Furthermore, the increased p53 protein levels in response to
PERP expression were accompanied by an increase in the
p53-negative regulator MDM2. As PERP is a transcriptional
target of p53, the increase in p53 protein in response to
PERP expression suggested a role for PERP in the positive
feedback regulation of p53. To determine if the observed
increase in p53 and MDM2 proteins was transcription-driven,
p53 and MDM2 transcriptional levels were determined
by real-time quantitative PCR (Q-PCR) in control and
GFP–PERP-expressing cells. There was no signiﬁcant
increase in p53 mRNA in cells expressing PERP compared
with GFP-only-expressing cells (T-test, PZ0.19). However,
MDM2 mRNA was signiﬁcantly higher in cells expressing
PERP at the three time points analyzed (T-test, Pr0.004;
Figure 1b). Taken together, the results suggested that
the increased p53 protein levels detected in response
to PERP expression may be a consequence of increased
p53 protein stability rather than transcription, and that the
ensuing p53 pool is likely to be transcriptionally active
resulting in increased MDM2 at both the transcriptional and
protein level.
There was also evidence that endogenous PERP protein
(21kDa) was slightly elevated in MEL202 cells at 72h
following transfection with GFP–PERP (Figure 1c). Owing to
the low basal level of endogenous PERP in MEL202 cells and
similar intensities of nonspeciﬁc proteins, the level of
endogenous PERP in response to GFP–PERP expression
was further investigated in the wild-type p53-expressing cell
lineU2OS.AnincreaseinendogenousPERPwasapparentin
U2OS cells at 48 and 72h following transfection with GFP–
PERP (Figure 1c). It was conceivable that the observed
increase in endogenous PERP was due to the GFP–PERP-
induced increased activity of its transcriptional regulator, p53.
Consequently, it was important to characterize the functional
status of the raised p53 protein following GFP–PERP
expression.
PERP expression inﬂuences the nuclear translocation
and the p53-driven expression of MDM2. The effect of
increased PERP expression described above was found in
transiently transfected cell populations where, on average,
the transfection efﬁciency was 13%. To reﬁne our ﬁndings,
we assessed the effect of PERP expression on the
subcellular localization and expression of the p53-
transcriptional target MDM2 in individual cells by co-
transfecting GFP–PERP with an expression plasmid in
which MDM2 was fused to yellow ﬂuorescent protein (YFP)
under the control of the human MDM2 native promoter that
was previously shown to mirror the kinetic behaviour of
endogenous MDM2.
20 The ﬁrst striking observation was the
almost exclusive nuclear localization of MDM2–YFP when
co-expressed with GFP–PERP (in 96.8% of co-transfected
cells; T-test, P¼0.02 and 0.04 versus MDM2–YFP or
MDM2–YFP and GFP-only; Figures 2a and b). In contrast,
MDM2–YFP expression alone or in combination with GFP-
only expression showed an additional diffuse cytoplasmic
localization of MDM2 in many cells (28 and 31%,
respectively; Figures 2a and b). Control cells transfected with
YFP-only presented a diffuse YFP expression throughout the
cytoplasm and nucleus, which was maintained following
co-expression of GFP–PERP (98% cells; Figures 2a and b).
To determine the effect of PERP on the expression of
MDM2, YFP ﬂuorescence was measured in cells co-expres-
sing GFP–PERP and MDM2–YFP and compared with that in
control cells (MDM2–YFP-transfected and GFP-only plus
MDM2–YFP co-transfected cells). The level of YFP ﬂuores-
cence – and therefore MDM2 expression – was signiﬁcantly
higher in cells co-expressing GFP–PERP compared with
cells co-expressing GFP-only and MDM2–YFP (T-test,
Po0.0001), or expressing MDM2–YFP alone (T-test,
Po0.0001; Figures 2c and d).
To directly assess the role of p53-driven transcription of
MDM2 in response to PERP expression, cells co-transfected
withGFP–PERP and MDM2–YFPwere treatedwith piﬁthrin-a
(PFTa), a reversible inhibitor of p53-dependent gene
transcription.
21 The level of MDM2–YFP ﬂuorescence in cells
co-expressing GFP–PERP was signiﬁcantly reduced in cells
treated with PFTa (T-test, Po0.0001; Figures 2e and f),
indicating that the induction of MDM2 expression in cells
expressing GFP–PERP was likely through p53-dependent
transcriptional activation. No signiﬁcant difference was seen
in control cells co-expressing GFP-only and MDM2–YFP with
or without PFTa treatment (T-test, P¼0.95).
PERP expression localizes p53 in the nucleus with
evidence of oscillatory activity. To monitor the effect of
PERP expression on the cellular localization of p53, MEL202
cells were co-transfected with GFP–PERP and an
expression plasmid in which p53 was fused to red
ﬂuorescent protein (RFP) placed under the control of a
zinc-inducible promoter. Cells transfected with p53–RFP-
only served as controls. In the absence of GFP–PERP
expression, p53–RFP was localized primarily in the
cytoplasm with low expression in the nucleus (65% of
transfected cells; Figures 3a and b), compared with 35% of
cells showing nuclear-only p53–RFP expression. However,
following GFP–PERP expression, p53–RFP was localized
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Cell Death and DiseaseFigure 1 PERP expression augments p53 and MDM2 protein level in MEL202 cells. (a) p53 and MDM2 proteins are increased in cells expressing GFP–PERP. MEL202
cells were transfected with GFP–PERP and lysates prepared at 24-, 48- and 72-h PT and analyzed by western blotting alongside NT and GFP-only-transfected cells that
served as controls. A431 cell lysate served as a positive control for the respective antibodies. PERP, p53 and MDM2 proteins were detected with appropriate antibodies and
their relative levels were quantiﬁed by densitometry and normalized to GAPDH. (b) Elevated PERP expression leads to increased MDM2 transcription. RNA was extracted
from MEL202 cells transfected with GFP-only or GFP–PERP expression plasmids at the indicated times PT. The levels of PERP, p53 and MDM2 mRNA were determined by
Q-PCR and normalized to the respective endogenous level of GAPDH. Normalized mRNA levels are expressed relative to the respective levels in GFP-only-transfected cells
that were given an arbitrary value of 1. The mean of three independent experiments along with S.D. is presented. (*T-test, Pr0.004 compared with GFP-only-transfected
cells). (c) Expression of exogenous PERP increases endogenous PERP protein. Representative western blots showing endogenous PERP protein level in control cells and
cells expressing GFP–PERP in MEL202 and U2OS cell lines; increased levels of endogenous PERP are detectable at 72-h PT in MEL202 cells and 48–72h in U2OS cells.
*a nonspeciﬁc protein that is consistently detected with the anti-PERP antibody
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Cell Death and Diseasepredominantly in the nucleus in a signiﬁcantly higher
proportion of co-transfected cells (58%; T-test, P¼0.04;
Figures 3a and b). Nuclear expression of p53–RFP when co-
expressed with GFP–PERP was also detected in the
absence of ZnCl2 induction, albeit at much lower
expression levels, and ZnCl2 had no effect on the
expression or localization of GFP–PERP (Figure 3c). The
PERP-induced nuclear localization of p53 suggests that p53
is likely to wield its transcriptional activity – a scenario that is
also supported by the p53-dependent upregulation of MDM2
transcription in the presence of elevated PERP (Figure 2).
Furthermore, the highest nuclear MDM2–YFP ﬂuorescence
in cells co-transfected with MDM2–YFP and p53–RFP
occurred when p53–RFP was also localized primarily in
the nucleus, while cytoplasmic p53 was associated
(ﬂuorescence colocalized) with cytoplasmic MDM2–YFP
(Figure 3d), illustrating the nuclear-cytoplasmic shuttling of
both p53 and MDM2 that is central to their activities.
15
As we had shown that the increase in MDM2 expression
in the presence of elevated PERP was p53-dependent
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Cell Death and Disease(Figure 2e), we next addressed the behaviour of p53 in the
presence of elevated PERP over time in cells co-expressing
GFP–PERP and MDM2–YFP. These cells were monitored by
time-lapseﬂuorescenceconfocalmicroscopyandtheMDM2–
YFP ﬂuorescence was assessed as a measure of the kinetic
behaviour of p53.
20 Full acquisition of YFP ﬂuorescence
measurements in a single cell over the entire time-lapse
period (usually at least 18h) proved difﬁcult because of the
high motility of MEL202 cells, which resulted in many cells
leaving the ﬁeld of view. However, we were able to detect
dampened oscillations in MDM2–YFP ﬂuorescence at regular
5–6h intervals (Figure 3e), which corresponded to previous
ﬁndings albeit in response to DNA damage.
20 We also
observed cell death in approximately 31% of cells expressing
GFP–PERP and MDM2–YFP over the time frame of imaging,
which corresponded to approximately 30–48-h post-transfec-
tion (PT). These levels of cell death were comparable with our
previous ﬁndings
5 and conﬁrmed that the observations of
MDM2–YFP expression in this study reﬂect the endogenous
response to GFP–PERP expression.
Endogenous MDM2 and p53 are predominantly nuclear
in the presence of elevated PERP expression. To verify
that the prevalent nuclear localization of MDM2–YFP and
p53–RFP seen in MEL202 cells following GFP–PERP
expression reﬂected the subcellular localization of
endogenous MDM2 and p53 in the presence of elevated
PERP, MEL202 cells were transfected with GFP–PERP and
ﬁxed 24-h PT. Endogenous MDM2 and p53 were detected by
immunoﬂuorescence. Every cell-expressing GFP–PERP that
was detected (52 cells) exhibited nuclear localization of
MDM2 and p53, whereas a mixture of nuclear, nuclear/
cytoplasmic or cytoplasmic expression of MDM2 and p53
was seen in NT cells (Figure 4). The ﬁxation and
immunoﬂuorescence procedure caused a signiﬁcant
detachment of GFP–PERP-transfected cells. This is likely
due to the pro-apoptotic effect of PERP on MEL202 cells
5
that causes more readily detachment during ﬁxation and
subsequent immunodetection.
P53 elevated by PERP expression is modiﬁed on key
phosphorylation sites. To determine if expression of
PERP results in speciﬁc p53 posttranslational modiﬁcation,
western blotting was used to assess the phosphorylation
status of key p53 Ser residues in the presence of enhanced
PERP expression. Phosphorylation at Ser15 was detected
in control cells (NT and GFP-only-transfected), but was
signiﬁcantly reduced in GFP–PERP-expressing cells (T-test,
Pr0.003 versus GFP-only-transfected cells; Figure 5a). No
signiﬁcant change in phosphorylation at Ser37 was detected.
In response to DNA damage, phosphorylation by ataxia
telangiectasia mutated and ataxia telangiectasia and Rad3
related at Ser15 and Ser37 can impair the interaction
between p53 and MDM2, promoting the accumulation and
activation of p53.
12,22 Consequently, reduction of phos-
phorylation at Ser15, and insigniﬁcant detection of Ser37P
suggest that impairment of the p53–MDM2 interaction by
phosphorylation at these two Ser residues does not contribute
to the increased p53 protein seen in response to PERP
expression. However, a signiﬁcant increase in the level of
Ser20 phosphorylation was observed in cells expressing GFP–
PERP (T-test, Pr0.004 versus GFP-only-transfected cells;
Figure 5a). As p53Ser20P is known to interfere with p53 binding
to MDM2,
23,24 it is possible that this modiﬁcation may contribute
to the PERP-related increased p53 accumulation.
Total p53 protein level, detected using anti-p53 antibody
(clone 7F5) conﬁrmed the upregulation of p53 protein in cells
transfected with GFP–PERP detected previously with a
different anti-p53 antibody (clone DO-1; Figure 1a), albeit
with a slightly higher p53 level in NT cells (Figure 5a).The
detection of p53Ser15P in cells in which total p53 was low/
undetectable (NT and GFP-only-transfected) is likely due to
differences in antibody speciﬁcity.
Phosphorylation of p53 at Ser46 was characterized as a
speciﬁc phosphorylation event that irreversibly commits cells
to apoptosis.
14,25 We detected the presence of p53Ser46P
in control MEL202 cells with signiﬁcantly higher levels in
GFP–PERP-expressing cells (T-test, Pr0.03 versus GFP-
only-transfected cells; Figure 5b), indicating that the p53
protein elevated in response to PERP expression is likely to
Figure2 PERPexpressioninﬂuencesthenucleartranslocationandthep53-drivenexpressionofMDM2.(a)PERPexpressionleadstopredominantlynuclearlocalization
of MDM2. MEL202 cells transfected with YFP-only, YFP-only and GFP–PERP, MDM2–YFP, MDM2–YFP and GFP-only, or MDM2–YFP and GFP–PERP were monitored by
confocal ﬂuorescence microscopy and the analysis of the intracellular distribution of proteins of interest was undertaken at 20-h PT. The number of cells exhibiting
predominantly nuclear MDM2 localization (N4C) or more even distribution in the nucleus and cytoplasm (NrC) were counted. Results are presented as the mean
percentage of transfected cells from three independent transfections in each scenario with S.D., with 200 cells counted for each transfection. MDM2 was predominantly
nuclear in a signiﬁcantly higher proportion of cells when co-expressed with GFP–PERP (*T-test, P¼0.02 and P¼0.04 versus MDM2–YFP or MDM2–YFP and GFP-only-
transfected cells, respectively). (b) Differential MDM2 subcellular distribution in the presence and absence of GFP-PERP. A predominantly nuclear MDM2–YFP localization
(yellow)isevidentincellsco-expressing GFP-PERP,incontrasttothediffusecytoplasmic/nuclearlocalizationofMDM2–YFPintheabsenceofGFP–PERPandof YFPalone
in control cells. Green ﬂuorescence shows the characteristic distribution of GFP or GFP–PERP proteins. The phase image of cells lacking GFP ﬂuorescence is shown. Scale
bar¼50mm. (c) Single cell analysis veriﬁed that PERP expression leads to increased MDM2 expression. MEL202 cells were transfected and monitored as described in (a).
Imageswere taken fromthree independent transfection experiments andYFP ﬂuorescencewas measured incells in arbitraryunits(AU). Mean YFPﬂuorescenceis indicated
(~) with S.D. MDM2–YFP ﬂuorescence was signiﬁcantly higher in cells co-expressing GFP–PERP (T-test, Po0.0001), compared with cells expressing GFP-only and
MDM2–YFP,orMDM2–YFP-only.ExpressionofGFPalonedidnotaffectthelevelsof MDM2(T-test,P¼0.55).(d)RepresentativeimagesshowingincreasedMDM2protein
in cells expressing PERP.MDM2–YFP ﬂuorescence (yellow)is indicatedin AU by the corresponding nucleus. GFP-only and,respectively,GFP–PERP expression are shown
ingreen.ThecorrespondingphaseimageofcellsexpressingMDM2–YFP-onlyisalsopresented.Scalebar¼50mm.(e)PERP-inducedMDM2expressionisp53dependent.
MEL202 cells were transfected with GFP–PERP, MDM2–YFP and GFP-only as indicated, in the presence (þ) for at least 14h, or absence ( )o f3 0mM PFTa. YFP
ﬂuorescence was measured in cells from three independent transfections. Mean YFP ﬂuorescence is indicated (~) with S.D. PFTa signiﬁcantly reduced the level of MDM2–
YFP expression in cells co-expressing GFP–PERP (T-test, Po0.0001). (f) Representative images of MEL202 cells co-expressing GFP–PERP (green) and MDM2-YFP
(yellow) in the presence and absence of PFTa. YFP ﬂuorescence (AU) measured in the nuclei of each cell is indicated. Scale bar¼50mm
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Cell Death and Diseasebe active in apoptosis regulation. The effect of PERP
expression on homeodomain-interacting protein kinase 2
(HIPK2) and p38 mitogen-activated protein kinase (MAPK)
(p38), both previously implicated in the induction of p53 Ser46
phosphorylation,
26–29 was also assessed by western blotting.
No signiﬁcant changes were detected in HIPK2 expression or
in the level of phospho-p38 (Thr180/Tyr182), suggesting the
possibility that different pathway(s) may be involved.
Q-PCR analysis of p53 target genes revealed a statistically
signiﬁcantupregulationofdeathreceptor4(DR4)andleucine-
rich repeats and death domain containing (LRDD), both pro-
apoptotic genes
30 in MEL202 cells expressing GFP–PERP
compared with GFP-only-expressing cells (Figure 5c). No
signiﬁcant changes occurred in the level of cyclin-dependent
kinase inhibitor 1A (p21) gene, involved in cell cycle arrest.
30
Discussion
The initial ﬁndings that elevated PERP expression resulted in
increased p53 protein levels in MEL202 cells suggested a role
for PERP in the positive feedback regulation of its own
transcriptional regulator, with potential implications for the
regulation of p53 and the vast array of p53-targets involved in
the tight control of cell cycle arrest and apoptosis. Conse-
quently, the study aimed to investigate, in real-time and live
cells, the nature of the observed p53 upregulation and the
functionality of the elevated p53.
The active status of the p53 elevated in response to PERP
expression was initially indicated by the simultaneous
increase in the p53-negative regulator protein, MDM2.
Q-PCR analysis conﬁrmed increased MDM2 transcription,
which most likely occurs through the well-characterized
Figure 3 p53 cellular localization is inﬂuenced by PERP expression and is subject to oscillatory regulation. (a) p53 localizes primarily in the nucleus following PERP
expression. MEL202 cells transfected with p53–RFP or p53-RFP and GFP–PERP were monitored by confocal ﬂuorescence microscopy and the analysis of the intracellular
distribution of proteins of interest was undertaken at 20-h PT. The number of cells exhibiting a predominant nuclear localization (N4C) or a more even p53 distribution in the
nucleus and cytoplasm (NrC) were counted and are presented as the mean percentage of transfected cells from three independent transfections with S.D. p53–RFP was
predominantly nuclear in a signiﬁcantly higher proportion of cells when co-expressed with GFP–PERP compared with cells expressing p53-RFP only (*T-test, P¼0.04).
(b)Representativeimagesshowingthepredominantcytoplasmiclocalizationofp53(red) intheabsenceof GFP–PERPexpression(leftpanel),andtheprevalentnuclearp53
localization (red) in the presence of GFP–PERP (green; right panel), following induction of the pMT promoter of p53–RFP with 100mM ZnCl2. Scale bar¼20mm. (c) ZnCl2
doesnotinﬂuencePERPexpressionorp53localization.Lowbasalexpressionofp53–RFPobservedintheabsenceofZnCl2inductionhadapredominantnuclearlocalization
in the presenceof GFP–PERP expression, whilst 100mM ZnCl2 had no effect on GFP–PERP expressionor localization.Scale bar¼20mm. (d) IncreasedMDM2 expression
occurs when p53 is primarily localized in nucleus. MEL202 cells were co-transfected with p53–RFP and MDM2-YFP and images were taken from three independent
transfections at 20-h PT. YFP ﬂuorescence was measured in arbitrary units (AU) in cells expressing p53 predominantly in the nucleus (N4C) or more evenly in the nucleus
andcytoplasm(NrC).Meanﬂuorescenceisindicated(~)withS.D.MDM2-YFPﬂuorescencewassigniﬁcantlyhigherincellsexpressingp53primarilyinthenucleus(T-test,
Po0.0005). Representative images of the differential localization of p53 (red) and MDM2 (yellow) are shown. Scale bar¼20mm. (e) PERP-induced elevated MDM2
expression exhibits oscillations. MEL202 cells co-transfected with GFP–PERP (green in bright ﬁeld) and MDM2-YFP (yellow) were monitored by time-lapse ﬂuorescence
microscopy. Nuclear MDM2–YFP ﬂuorescence was measured (AU) in single cells over time (hours) and data are presented graphically alongside corresponding time point
images. An arrow indicates the relevant cell where necessary
Figure 4 Endogenous MDM2 and p53 are primarily nuclear in the presence of GFP–PERP expression. Endogenous MDM2 (blue; left panel) and p53 (blue; right panel)
proteins were detected in ﬁxed GFP–PERP-transfected MEL202 cells and NT cells within the same cell population by immunoﬂuorescence. NT cells displayed a mixture of
cytoplasmic (NrC) and nuclear (N4C) endogenous MDM2 and p53, while every detected cell expressing GFP–PERP (green) presented a nuclear MDM2 or p53
localization. Cells incubated with secondary antibody only veriﬁed anti-MDM2 antibody speciﬁcity and MEL202 cells transfected with p53–GFP (green) and subjected to UV
treatment (20mJ/cm
2) served as a positive control for anti-p53 antibody. Scale bar¼200mm
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10,11 Single cell
analysis corroborated that elevated levels of PERP protein
positively inﬂuenced the transcription level of MDM2, which
was p53 dependent. Thus, the p53 that is augmented in
response to PERP expression is transcriptionally active and
able to function in its transcriptional regulatory role.
In the absence of exogenous PERP, p53 was localized
primarily in the cytoplasm of MEL202 cells. P53 localization
outside the nucleus occurs in many tumour cells
3 and was
proposed as a mechanism employed by neoplastic cells to
inactivate p53 transactivation function.
2 Cytoplasmic reten-
tion of p53 renders tumour cells less responsive to genotoxic
stress
15 and correlates with resistance to chemo- and
radiotherapy in many tumour types,
15,31,32 although this does
not preclude the transcriptional-independent, mitochondrial-
related p53 function leading to apoptosis.
33 Notably,
GFP–PERP expression resulted in predominantly nuclear
localization of p53 and MDM2, as well as higher MDM2
transcription. Colocalization of p53 and MDM2, in the
cytoplasm or the nucleus, can promote the MDM2-mediated
proteasomal degradation of p53 without nuclear to cytoplas-
mic transport.
34 However, cytoplasmic localization of MDM2
in controlcells lacking GFP–PERP expression suggested that
nuclear-cytoplasmic shuttling of MDM2 is also occurring.
16
Furthermore, time-lapse analysis of individual cells co-
expressing GFP–PERP and MDM2–YFP provided evidence
Figure 5 p53elevatedbyPERPexpression ismodiﬁedon keyphosphorylation sites.(a)Differentialphosphorylationofp53residuesinvolvedinMDM2interactionincells
expressing PERP. MEL202 cells were transfected with GFP–PERP and lysates prepared at 24-, 48- and 72-h PT and analyzed by western blotting alongside NT and GFP-
only-transfected cellsthat served as controls. A431 and Jurkatcell lysatesserved as positive controlsfor the respective antibodies.Phospho-p53 proteins, phosphorylated on
speciﬁc serine (Ser) residues as indicated, were detected with appropriate antibodies (see Materials and methods section) and their relative levels were quantiﬁed by
densitometry and normalized to GAPDH. In cells expressing GFP–PERP, p53Ser15P was signiﬁcantly reduced (*T-test, Pr0.003) whereas p53Ser20P was signiﬁcantly
increased (*T-test, Pr0.004), compared with cells transfected with GFP–only. Total p53 protein detected with anti-p53 antibody (clone 7F5) is also presented.
(b)Phosphorylationatp53Ser46isincreasedincellsexpressingPERP.ControlandtransfectedMEL202cellswereanalyzedasin(a)forphosphorylationofp53atSer46.UV-
treated HeLa cell lysate served as a positive control for the anti-p53Ser46 antibody. P53Ser46P was signiﬁcantly higher in cells transfected with GFP–PERP compared with
GFP-only-transfectedcells(*T-test,Pr0.03).NosigniﬁcantchangesinHIPK2orphospho-p38(Thr180/Tyr182)proteinlevelsweredetected.PC-12andUV-treatedCOScell
lysates served as controls for anti-HIPK2 and anti-phospho-p38/anti-GAPDH, respectively. (c) Elevated p53 induced by PERP expression may enhance activation of speciﬁc
pro-apoptotic p53 target genes. The levels of p53 target genes DR4 and LRDD (pro-apoptotic genes) and p21 (involved in cell cycle arrest) in MEL202 cells expressing GFP-
only (control) and GFP–PERP were determined by Q-PCR at 24-h PT. mRNA levels normalized to the endogenous level of GAPDH are expressed relative to the respective
levels of mRNA in GFP-only-expressing cells that were given an arbitrary value of 1. The mean of three independent experiments along with S.D. is presented. The level of
DR4 and LRDD mRNA was signiﬁcantly higher in GFP-PERP-transfected cells compared with control cells (*T-test, P¼0.04 and P¼0.005, respectively). There was no
signiﬁcant difference in the level of p21 (T-test, P¼0.50)
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regular pulses in MDM2 at 5–6-h intervals, analogous
with previously reported oscillatory behaviour of p53 in
DNA-damaged cells.
20
Cell death following co-expression of GFP–PERP with
MDM2–YFP was consistent with the previously observed
level of apoptosis in GFP–PERP-expressing MEL202 cells,
5
substantiating the ﬁnding that elevated PERP is sufﬁcient to
induce apoptosis in MEL202 cells via the caspase-dependent
pathway,
5 downstream of the p53/MDM2 feedback loop
junction. Consistent apoptotic levels also conﬁrm that the
transcriptional changes in MDM2–YFP following GFP–PERP
expression are representative of endogenous processes in
MEL202 cells. Taken together, current ﬁndings indicate that
the pro-apoptotic effect of PERP involves and may be
ampliﬁed by the effect PERP expression has on its own
transcriptional regulator p53. In line with our previous
observations, PERP was targeted to the plasma membrane
of MEL202 cells.
5 A cytoplasmic and nuclear distribution of
PERP has been recently described in renal tubular epithelial
cells
8andthepotentialforinteractionofPERPwithp53and/or
MDM2 in these subcellular compartments cannot be ruled out
at present.
Evidence that differential phosphorylation of key Ser
residues of p53 occurs following PERP expression indicates
that the elevated p53 is subject to posttranslational modiﬁca-
tions that associate with p53 activation. Phosphorylation at
p53Ser15, Ser20 and Ser37 can lower the afﬁnity between
p53 and MDM2, resulting in their reduced interaction and the
subsequent accumulation of p53.
13,22,23 Our results showed
that p53Ser15 phosphorylation is reduced in cells expressing
PERP, however, a slight but signiﬁcant increase in the level of
p53Ser20 phosphorylation was detected in the presence of
elevated PERP. Phosphorylation at Ser20 enhances p53
tetramerization, nuclear accumulation, stability and transcrip-
tional activity,
23,24 and therefore it is likely that this modiﬁca-
tion contributes to the stability and increased levels of nuclear
p53 seen in response to PERP expression.
Of particular interest was the increased level of p53Ser46
phosphorylation; this modiﬁcation is speciﬁcally involved in
regulating the ability of p53 to induce apoptosis
25 by
preferentially activating the transcription of pro-apoptotic
p53-target genes.
14,33 The p53 afﬁnity switch from promoters
of cell cycle arrest-related genes to apoptotic-related ones
usually requires severe, non-repairable DNA damage.
14,25,35
The increase in p53Ser46P induced by PERP expression is
likely insufﬁcient to drive the switch of gene–promoter targets
tothelevelseeninresponsetogenotoxicstress.However,we
observed an upregulation of DR4 and LRDD, both p53-
induced pro-apoptotic genes,
30 with no change in the cell
cycle arrest-related gene, p21. Detection of p53Ser46P in
control cells (NT and GFP-only-transfected) suggests that
other cell signals are contributing to p53 phosphorylation
induction. PERP expression may enhance these signals or
may render p53 more susceptible to Ser46 phosphorylation.
Initial experiments suggest that p53Ser46 phosphorylation in
response to PERP may occur by processes other than HIPK2
or p38 activation. Further studies will be required to elucidate
the precise mechanism of p53 phosphorylation in response to
PERP expression.
Our ﬁndings that PERP can act by increasing p53 protein,
which is both transcriptionally active and subject to apoptosis-
linked phosphorylation events, suggest the existence of an
amplifying positive feedback loop at the functional level of p53
that may tip the balance in favour of p53-dependent apoptosis
rather than cell cycle arrest and/or lead to increased PERP
levels that in turn promote apoptosis. The ﬁnding that PERP
can only partially reconstitute the level of apoptosis in p53-null
cells
4 also supports the existence of a PERP–p53 positive
regulatory loop. Consequently, cells lacking functional PERP
may also be impaired in their ability to regulate levels of p53.
Downregulation of PERP correlates with the aggressive
monosomy-3 type of UM,
17 a disease in which the upstream
signalling to p53 is reportedly intact, but functional defects
downstream of p53 were inferred.
36 Many tumours express
p53 mutants with a reduced ability to activate p53-target gene
expression that normally respond to wild-type p53 activa-
tion.
3,37 This study demonstrates the transcriptional activity of
p53inMEL202cellsandreﬂectsthereportedlowfrequencyof
p53 mutations in primary UMs.
36,38,39 Our previous ﬁndings
that UM cells, including MEL202 cells, readily commit to
apoptosis in response to upregulation of PERP expression
5
imply that the downstream cell death pathway required for
PERP-induced apoptosis is intact and functional in UM cells.
The scenario of a downstream target of p53, such as PERP,
inﬂuencing levels of its own transcriptional regulator is
conceivable because loss of PERP function in these cells
would not only have a detrimental effect on downstream
signalling involving caspase-mediated apoptosis,
5 but may
also adjust p53 levels that inﬂuence the ﬁne balance between
cell death and survival. Deregulation of PERP appears as a
mechanism engaged by UM cells to escape death by
apoptosis.
5,17
In summary, this study identiﬁes a novel role for PERP in
stabilizing active p53 levels and places PERP at a signalling
junction that can inﬂuence both upstream and downstream
pathways of p53. Although interpretation of experiments
involving manipulation of expression levels of p53-linked
proteins should always be made with caution because of
potentially abnormal or unregulated interactions with other
proteins,
3 our data show that increased PERP expression
affects several aspects of p53 regulation, including increased
protein stability, apoptosis-promoting posttranslational mod-
iﬁcations, enhanced nuclear accumulation, and oscillatory
regulation. Our ﬁndings highlight a potentially important target
for development of cancer therapies aimed at enhancing p53
apoptotic activity and reconstituting the p53-dependent
apoptotic pathway.
Materials and Methods
Cell culture. Tissue culture media and supplements were from Invitrogen
(Paisley, UK), unless otherwise stated. The UM cell line MEL202
19 was grown in
RPMI-1640 medium with 2mM L-glutamine and 25mM HEPES supplemented with
10% v/v heat-inactivated fetal calf serum (FCS; Biosera, East Sussex, UK), 1mM
sodium pyruvate and 1% v/v non-essential amino acids. U2OS cells (ATCC No:
HTB-96; LGC Standards, Teddington, Middlesex, UK) were grown in Dulbecco’s
modiﬁedEagle’smediumwith L-glutamineand10%FCS.Cellsweregrownat371C
in controlled humidity and 5% CO2 atmosphere.
Plasmid constructs and transient transfection of cell lines. The
pcDNA-DEST53 plasmid containing GFP fused to the N-terminus of the full-length
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was constructed as described previously.
5 The pEGFP-N1 vector (Clontech, Palo
Alto, CA, USA) encoding GFP-only and pG-A-EYFP vector encoding YFP-only
(kindly supplied by Louise Ashall, University of Liverpool, UK) served as controls.
The pU293 plasmid encoding human MDM2 fused to enhanced YFP under the
control of the human MDM2 native promoter (MDM2–YFP
20) and pU265 containing
p53 ORF fused to DsRed-Express RFP under a zinc-inducible pMT promoter
(p53-RFP) were kind gifts from Galit Lahav (Weizmann Institute of Science, Israel)
and Rachel Nelson (University of Liverpool, UK), respectively. To induce p53–RFP
expression, zinc chloride (Sigma-Aldrich, Poole, UK) was added to cell media in a
ﬁnal concentration of 100mM, 6-h PT. The pp53-EGFP Vector (Clontech) encoded
p53 fused to enhance GFP (p53–GFP) under the CMV promoter. Transient
transfections were performed using GeneJuice Transfection Reagent (Novagen,
Merck Biosciences Ltd., Darmstadt, Germany). Cells were transfected with 1mg
plasmidDNAper35mmdish.Forco-transfections,thetotalamountofplasmidDNA
used was always 1mg.
Laser scanning confocal ﬂuorescence microscopy of live
transfected cells. Live cell imaging of transfected cells was performed in an
incubator XL (PeCon GnbH) on the microscope stage that was humidity controlled at
371Cw i t h5 %C O 2. Cells were imaged using a LSM 5 EXCITER Laser Scanning
Microscope (Carl Zeiss, Welwyn Garden City, Hertfordshire, UK) using a Fluar 40X/
1.3 NAoil immersion objective. Images were taken from20-h PT. Excitation of EGFP
was achieved with a 488nm laser, and the emitted light was collected through a
505–530nm bandpass ﬁlter from a 545nm dichroic mirror (515nm dichroic mirror
when in combination with YFP); YFP was excited at 514nm (or at 488nm when in
combination with RFP) and its emission detected through a 515nm dichroic mirror
and a 505–550nm BP ﬁlter; RFP was excited at 543nm and its emission detected
through a 545nm dichroic mirror and a 560nm longpass ﬁlter. Data acquisition and
analysis were carried out with LSM510 AIM software, version 4.2 (Carl Zeiss) and
ImageJ 1.43h.
40 Cell death was assessed as described previously.
5
PFTa treatment. Cells were treated with 30mM PFTa (Sigma-Aldrich) at 6-h
PT and images were taken from 20-h PT.
Westernblotanalysisandantibodies. Lysateswerepreparedfrom cells
at the indicated times as described previously
5 and resolved by SDS-PAGE before
transfer tonitrocellulosemembrane.Themembranes wereincubatedovernightat41C
withtheappropriateprimary antibody dilutedwith5% w/v non-fat dry milk or 5%bovine
serum albumin (BSA) in tris-buffered saline-Tween-20 buffer (TBS-T) buffer (20mM
Tris-HCl, 150mM NaCl, pH 7.6 with 0.1% v/v Tween-20) as recommended by the
manufacturer. The primary antibody dilutions used were as follows: anti-PERP
polyclonal (1:1000 dilution) and anti-GAPDH monoclonal (clone 6C5, 1:10000)
(Abcam, Cambridge, UK); anti-p53 monoclonal (clone DO-1, 1:1000) and anti-MDM2
monoclonal (clone 2A10, 1:1000) (Calbiochem, Merck Biosciences Ltd., Darmstadt,
Germany); anti-HIPK2 monoclonal (clone F-189, 1:200) (Santa Cruz Biotechnology,
Inc., Santa Cruz, CA, USA); anti-phospho-p38 MAPK monoclonal (Thr180/Tyr182)
(clone 3D7, 1:1000) and Phospho-p53 Antibody Sampler Kit including anti-phospho-
p53 (Ser15 monoclonal; Ser20, Ser37, Ser46, polyclonal; 1:1000) and anti-p53
monoclonal (clone 7F5, 1:1000) (Cell Signaling Technology, Beverly, MA, USA).
Immunocomplexes were detected with horseradish peroxidase-conjugated secondary
antibody (Sigma-Aldrich) by a chemiluminescent method (Amersham ECL Western
Blotting Detection Reagents, GE Healthcare Life Sciences, Little Chalfont,
Buckinghamshire, UK), with 2-min exposure to autoradiography ﬁlms unless
otherwise stated. Sequential probing of blots with different antibodies was achieved
by incubation in stripping solution (62.5mM Tris-HCl, pH 6.8, 100mM
b-mercaptoethanol, 2% w/v SDS) at 65
oC for 30min, followed by 2 10min
washes in TBS-T at room temperature, before blocking in 5% milk/TBS-T and
reprobing with antibody. Detection of phospho-p53 products was carried out using
separate blots of identical samples rather than sequential probing of the same blot to
prevent carry-over of previously detected p53 products. Blots were probed with anti-
GAPDH to conﬁrm equal loading of samples. Relative intensities of the protein bands
were obtained by densitometry using ImageJ (Rasband, WS, ImageJ, US National
Institutes of Health, Bethesda, MD, USA, http://rsb.info.nih.gov/ij/, 1997–2007) and
normalizedtoendogenousGAPDH.Westernblotimagespresentedarerepresentative
of three independent experiments.
Immunoﬂuorescence. MEL202 cells were seeded in eight-well Lab-Tek
Chamber Slide (Nunc, Rochester, NY, USA) 24h before transfection. Media was
removed 24h following transfection and cells were washed in phosphate-buffered
saline (PBS). Cells were ﬁxed with freshly prepared 4% paraformaldehyde in PBS
for 10min followed by 3 5min washes. Following permeabilisation with 0.3%
Triton X-100 in PBS for 5min and a 5min PBS wash, cells were incubated in
blocking buffer (5% normal goat serum in PBS) for 60min before incubating with
primary antibody diluted in antibody dilution buffer (1% BSA in PBS) for 60min.
Cells were washed for 3 5min in PBS before addition, where necessary, of
diluted ﬂuorochrome-conjugated secondary antibody for 45min, followed by
3 5min washes in PBS. All incubations were carried out at room temperature.
Cells were coverslipped with Fluorescence Mounting Medium (Dako,
Cambridgeshire, UK) and examined using a LSM 5 EXCITER Laser Scanning
Microscope (Carl Zeiss) with excitation at 633nm. The primary antibody dilutions
used were: anti-MDM2 monoclonal (clone 2A10, 1:100) (Calbiochem, Merck
Biosciences); anti-p53 Alexa Fluor 647 Conjugate monoclonal (clone 1C12, 1:50)
(Cell Signaling Technology). The secondary antibody used for detection of MDM2
was Alexa Fluor 633 goat anti-mouse IgG (HþL; 1:500) (Invitrogen).
Real-time quantitative PCR. RNA was isolated from cells using RNeasy Kit
(Qiagen Ltd. West Sussex, UK) with on-column DNase I treatment for removal of
genomicDNA.First-strandcDNAwassynthesizedfrom1mgRNAusingSuperscript
IIReverseTranscriptase(Invitrogen).Real-timeQ-PCRwasperformedusingqPCR
Core Kit for SYBR Green I (Eurogentec, Southampton, UK) as described
previously.
5 The gene-speciﬁc primer set used for PERP was 50-GGCTTCATCATC
CTGGTGAT-30 and 50-ACAGCAGCCAAGGCAAGGAG-30; for p53, 50-ATCTACAA
GCAGTCACAGCAC-30 and 50-TTCCTTCCACTCGGATAAGATGC-30; and for
MDM2, 50-CCTGGCTCTGTGTGTAATAAG-30 and 50- ATCCAACCAATCACCT
GAATG-30. Primer sets for the p53-target genes
30 PUMA, DR4, DR5, LRDD and
p21werepurchasedfromSABiosciences(Qiagen).Q-PCRdatawerenormalizedto
GAPDH (primer set: 50-AACAGCCTCAAGATCATCAG-30 and 50-TGAGTCCT
TCCACGATACC-30). Ampliﬁcationswere performedin triplicateusinga Stratagene
MX3000P QPCR System (Stratagene, La Jolla, CA, USA). Q-PCR data are
expressed relative to a calibrator sample assigned an arbitrary quantity of 1.
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